Activating HER2 mutations as emerging targets in multiple solid cancers.

ESMO Open · 2017 · PMC5708307 · PMID 29209536

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

a trend towards significanceP=0.075so close (0.05 < p ≤ 0.1)

Analysing data from in vitro drug screening of these cell lines, through the Genomics of Drug Sensitivity in Cancer project (GDSC; release 6.1 52 ), we found afatinib IC50 values to be widely distributed among HER2 mutant cell lines, with a trend towards significance with afatinib sensitivity when compared with HER2 wild-type cancer cell lines (P=0.075; 9 HER2 mutant cell lines tested).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.